Your browser doesn't support javascript.
loading
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
Neuen, Brendon L; Heerspink, Hiddo J L; Vart, Priya; Claggett, Brian L; Fletcher, Robert A; Arnott, Clare; de Oliveira Costa, Julianna; Falster, Michael O; Pearson, Sallie-Anne; Mahaffey, Kenneth W; Neal, Bruce; Agarwal, Rajiv; Bakris, George; Perkovic, Vlado; Solomon, Scott D; Vaduganathan, Muthiah.
Affiliation
  • Neuen BL; The George Institute for Global Health, University of New South Wales, Sydney, Australia (B.L.N., H.J.L.H., R.A.F., C.A., B.N., V.P.).
  • Heerspink HJL; Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia (B.L.N.).
  • Vart P; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.L.N., B.L.C., S.D.S., M.V.).
  • Claggett BL; The George Institute for Global Health, University of New South Wales, Sydney, Australia (B.L.N., H.J.L.H., R.A.F., C.A., B.N., V.P.).
  • Fletcher RA; Department of Clinical Pharmacy and Pharmacology, University of Groningen, The Netherlands (H.J.L.H., P.V.).
  • Arnott C; Department of Clinical Pharmacy and Pharmacology, University of Groningen, The Netherlands (H.J.L.H., P.V.).
  • de Oliveira Costa J; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (B.L.N., B.L.C., S.D.S., M.V.).
  • Falster MO; The George Institute for Global Health, University of New South Wales, Sydney, Australia (B.L.N., H.J.L.H., R.A.F., C.A., B.N., V.P.).
  • Pearson SA; The George Institute for Global Health, University of New South Wales, Sydney, Australia (B.L.N., H.J.L.H., R.A.F., C.A., B.N., V.P.).
  • Mahaffey KW; Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia (C.A.).
  • Neal B; Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health, UNSW Sydney, Australia (J.d.O.C., M.O.F., S.-A.P.).
  • Agarwal R; Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health, UNSW Sydney, Australia (J.d.O.C., M.O.F., S.-A.P.).
  • Bakris G; Medicines Intelligence Research Program, School of Population Health, Faculty of Medicine and Health, UNSW Sydney, Australia (J.d.O.C., M.O.F., S.-A.P.).
  • Perkovic V; Stanford Center for Clinical Research, Stanford University School of Medicine, CA (K.W.M.).
  • Solomon SD; The George Institute for Global Health, University of New South Wales, Sydney, Australia (B.L.N., H.J.L.H., R.A.F., C.A., B.N., V.P.).
  • Vaduganathan M; Department of Epidemiology and Biostatistics, Imperial College London, United Kingdom (B.N.).
Circulation ; 149(6): 450-462, 2024 02 06.
Article in En | MEDLINE | ID: mdl-37952217
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Diabetes Mellitus, Type 2 / Diabetic Nephropathies / Renal Insufficiency, Chronic / Sodium-Glucose Transporter 2 Inhibitors Limits: Humans / Middle aged Language: En Journal: Circulation Year: 2024 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Diabetes Mellitus, Type 2 / Diabetic Nephropathies / Renal Insufficiency, Chronic / Sodium-Glucose Transporter 2 Inhibitors Limits: Humans / Middle aged Language: En Journal: Circulation Year: 2024 Type: Article